Suchergebnisse - "Bakris, George"

PubPharm (43)

1

Finerenone cardiovascular and kidney outcomes by age and sex : FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials

enthalten in: BMJ open | 2024

von Bansal, S. | Canziani, M. | Birne, R. | +10

2

Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis : A FIDELITY subgroup analysis

enthalten in: Diabetes, obesity & metabolism | 2024

von Perakakis, N. | Bornstein, S. | Birkenfeld, A. | +12

3

Finerenone in Black Patients With Type 2 Diabetes and CKD : A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials

enthalten in: Kidney medicine | 2023

von Flack, J. | Agarwal, R. | Anker, S. | +14

4

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis

enthalten in: Annals of internal medicine | 2023

von Agarwal, R. | Tu, W. | Farjat, A. | +112

5

Finerenone in Hispanic Patients With CKD and Type 2 Diabetes : A Post Hoc FIDELITY Analysis

enthalten in: Kidney medicine | 2023

von Rosas, S. | Ruilope, L. | Anker, S. | +14

6

The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone : Post hoc analysis of the FIDELITY study

enthalten in: Diabetes, obesity & metabolism | 2023

von Rossing, P. | Anker, S. | Filippatos, G. | +12

7

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone

enthalten in: JAMA cardiology | 2023

von Agarwal, R. | Pitt, B. | Rossing, P. | +12

CommentIn: JAMA Cardiol. 2023 Aug 1;8(8):742-743. - PMID 37314793

8

Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline

enthalten in: Diabetes, obesity & metabolism | 2023

von McGill, J. | Agarwal, R. | Anker, S. | +13

9

Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease

enthalten in: Postgraduate medicine | 2023

von Lerma, E. | White, W. | Bakris, G.

10

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

enthalten in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2023

von Green, J. | Mottl, A. | Bakris, G. | +8

1
2
3
4
5
Nächster »
[5]